Using a QbD approach in the development and formulation of topical products will enable the drug developer to provide a robust control strategy for manufacturing.
Sarah Pratt
Advertisement
Sarah Pratt is chief operating officer at MedPharm.
Articles by Sarah Pratt
Using a QbD approach in the development and formulation of topical products will enable the drug developer to provide a robust control strategy for manufacturing.
Advertisement
Latest Updated Articles
QbD Strategies to Secure the Scale-Up of Semi-Solid Topical FormulationsPublished: September 2nd 2018 | Updated:
Process Development Best Practices for Topical Drug ProductsPublished: February 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
2
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
3
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
4
PharmTech Weekly News Roundup – Week of November 3, 2025
5
